Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 Apr;3(4):375.
doi: 10.1038/s43018-022-00377-y.

Circumventing the roadblocks to targeting EGFR-driven cancers

No authors listed
Editorial

Circumventing the roadblocks to targeting EGFR-driven cancers

No authors listed. Nat Cancer. 2022 Apr.
No abstract available

PubMed Disclaimer

Comment on

  • An allosteric inhibitor against the therapy-resistant mutant forms of EGFR in non-small cell lung cancer.
    To C, Beyett TS, Jang J, Feng WW, Bahcall M, Haikala HM, Shin BH, Heppner DE, Rana JK, Leeper BA, Soroko KM, Poitras MJ, Gokhale PC, Kobayashi Y, Wahid K, Kurppa KJ, Gero TW, Cameron MD, Ogino A, Mushajiang M, Xu C, Zhang Y, Scott DA, Eck MJ, Gray NS, Jänne PA. To C, et al. Nat Cancer. 2022 Apr;3(4):402-417. doi: 10.1038/s43018-022-00351-8. Epub 2022 Apr 14. Nat Cancer. 2022. PMID: 35422503 Free PMC article.
  • Functional patient-derived organoid screenings identify MCLA-158 as a therapeutic EGFR × LGR5 bispecific antibody with efficacy in epithelial tumors.
    Herpers B, Eppink B, James MI, Cortina C, Cañellas-Socias A, Boj SF, Hernando-Momblona X, Glodzik D, Roovers RC, van de Wetering M, Bartelink-Clements C, Zondag-van der Zande V, Mateos JG, Yan K, Salinaro L, Basmeleh A, Fatrai S, Maussang D, Lammerts van Bueren JJ, Chicote I, Serna G, Cabellos L, Ramírez L, Nuciforo P, Salazar R, Santos C, Villanueva A, Stephan-Otto Attolini C, Sancho E, Palmer HG, Tabernero J, Stratton MR, de Kruif J, Logtenberg T, Clevers H, Price LS, Vries RGJ, Batlle E, Throsby M. Herpers B, et al. Nat Cancer. 2022 Apr;3(4):418-436. doi: 10.1038/s43018-022-00359-0. Epub 2022 Apr 25. Nat Cancer. 2022. PMID: 35469014

References

    1. Friedlaender, A. et al. Nat. Rev. Clin. Oncol. https://www.nature.com/articles/s41571-021-00558-1 (2022).
    1. Passaro, A. et al. Nat. Cancer https://doi.org/10.1038/s43018-021-00195-8 (2021). - DOI - PubMed
    1. To, C. et al. Nat. Cancer https://doi.org/10.1038/s43018-022-00351-8 (2022). - DOI - PubMed
    1. Marasco, M. & Misale, S. Nat. Cancer https://doi.org/10.1038/s43018-022-00365-2 (2022). - DOI - PubMed
    1. Herpers, B. et al. Nat. Cancer https://doi.org/10.1038/s43018-022-00359-0 (2022). - DOI